OKYO Pharma Ltd. Form 6-K Summary
Filing date: October 5, 2023. The filing reports a corporate announcement regarding OKYO’s lead drug candidate, OK-101. The company is a foreign private issuer that files annual reports on Form 20-F.
Business Context and Reporting Period
OK-101 was being evaluated in an ongoing 240-patient, double-blind, placebo-controlled Phase 2 trial in patients with dry eye disease (DED). Patients remained in the study, and the trial remained blinded while participants completed the 12-week dosing period.
Financial and Operating Metrics
This Form 6-K does not provide revenue, profit, cash flow, margin, debt, liquidity, or other financial metrics.
Material Changes Versus Prior Period
The filing does not provide comparative financial information or identify material changes versus a prior comparable period. The disclosed development is that OK-101 was showing a positive safety profile in the ongoing Phase 2 study.
Outlook, Risks, and Unusual Items
- OKYO stated that it would continue monitoring trial progress and the safety profile.
- Top-line Phase 2 data were expected in December 2023, subject to completion of the remaining 12-week dosing periods and continued trial execution.
- The study remained double-blind at the filing date, so efficacy results were not disclosed.
- A positive safety profile does not establish efficacy, regulatory approval, or commercial viability.
- The announcement was furnished as Exhibit 99.1 and was not deemed “filed” for purposes of Section 18 of the Securities Exchange Act, except as otherwise expressly provided.
Key Facts for Investors to Verify
- Whether the 240-patient Phase 2 DED trial completed as planned.
- The December 2023 top-line efficacy and safety results for OK-101.
- Any subsequent regulatory, clinical, or partnering developments.
- The company’s cash position, financing needs, and liquidity, which are not disclosed in this filing.